Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Dec. 10, 2021 - Puma Biotechnology Presents Updates from the SUMMIT trial at the 2021 SABCS Annual Meeting Read
- Dec. 3, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Nov. 23, 2021 - Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib) Read
- Nov. 20, 2021 - Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT trial at the 2021 SNO Annual Meeting Read
- Nov. 19, 2021 - Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS) Read
- Nov. 4, 2021 - Puma Biotechnology Reports Third Quarter 2021 Financial Results Read
- Oct. 21, 2021 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read
- Oct. 6, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Sept. 21, 2021 - Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference Read
- Sept. 7, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Sept. 7, 2021 - Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Read
- Aug. 6, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Aug. 5, 2021 - Puma Biotechnology Reports Second Quarter 2021 Financial Results Read
- July 26, 2021 - Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital Read
- July 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read
- July 15, 2021 - NCCN Announces Selected Projects to Study Neratinib in Collaboration with Puma Biotechnology Read
- July 2, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- July 1, 2021 - FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer Read
- June 4, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- June 4, 2021 - Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT trial at the 2021 ASCO Annual Meeting Read
- June 4, 2021 - Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL trial with the Neratinib Arm of the Phase III ExteNET trial at the ASCO 2021 Annual Meeting Read
- June 4, 2021 - Puma Biotechnology Presents Data from the Phase III ExteNET trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting Read
- May 19, 2021 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting Read
- May 6, 2021 - Puma Biotechnology Reports First Quarter 2021 Financial Results Read
- May 4, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- April 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Read
- April 13, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- March 8, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- March 4, 2021 - Puma Biotechnology to Present at the Barclays Global Healthcare Conference Read
- March 2, 2021 - Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference Read
- Feb. 25, 2021 - Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China Read
- Feb. 25, 2021 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Read
- Feb. 11, 2021 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results Read
- Feb. 9, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Jan. 29, 2021 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020 Read
- Jan. 19, 2021 - Puma Biotechnology to Present at the B. Riley Oncology Investor Conference Read
- Jan. 15, 2021 - Puma Biotechnology Presents Interim Results from the Biliary tract Cancers Cohort of the Phase II SUMMIT “Basket” trial of Neratinib at ASCO GI Read
- Jan. 5, 2021 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference Read
- Jan. 4, 2021 - Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference Read